SEAGEN INC (SGEN)
US81181C1045 - Common Stock
SEAGEN INC
NASDAQ:SGEN (12/13/2023, 8:12:24 PM)
After market: 228.95 +0.21 (+0.09%)228.74
-0.16 (-0.07%)
Company Profile
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Company Info
SEAGEN INC
21823 30Th Drive Se, Suite
Bothell WASHINGTON 98021
P: 14255274000
CEO: Clay B. Siegall
Employees: 3256
Website: https://www.seagen.com/
SGEN News
2 months ago - BloombergSeagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of CancersThe former chief of Seagen Inc., the cancer company Pfizer Inc. bought last year for $43 billion, has started a new company that uses a promising two-pronged approach to fighting tumors.
6 months ago - BloombergPfizer to ‘Catch Our Breath’ on Deals After $43 Billion PurchasePfizer Inc. Chief Executive Officer Albert Bourla said the pharma giant is pausing big acquisitions after spending $43 billion last year on buying Seagen Inc.
9 months ago - BloombergBiotech Rally Gets $100 Billion M&A Lift With More Deals to ComeA rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca Plc’s $1 billion deal to acquire closely-held Amolyt Pharma illustrates, the likelihood is there’s much more to come.
10 months ago - InvestorPlace3 Steal-of-a-Deal Stocks to Snap Up Right NowHere are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now.
10 months ago - InvestorPlaceGet Rich Quick with These 7 Growth Stocks to Buy NowHere are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand.
10 months ago - InvestorPlace7 Dividend Stocks to Buy at a 52-Week LowEach of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.
SGEN Twits
Here you can normally see the latest stock twits on SGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
